TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.05M | -55.58M | -54.67M | -64.31M | -59.36M |
| Total Depreciation and Amortization | 744.00K | 745.00K | 732.00K | 688.00K | 684.00K |
| Total Amortization of Deferred Charges | 612.00K | 434.00K | 267.00K | -- | -- |
| Total Other Non-Cash Items | -2.61M | 16.20M | 6.14M | 11.95M | 7.56M |
| Change in Net Operating Assets | -9.55M | -6.11M | -7.60M | 737.00K | 537.00K |
| Cash from Operations | -40.84M | -44.31M | -55.13M | -50.94M | -50.58M |
| Capital Expenditure | -345.00K | -667.00K | -676.00K | -647.00K | -588.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -1.00M | -1.00M | -1.00M | -1.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 1.00M | 66.00K | 67.00K | 0.00 |
| Cash from Investing | -345.00K | -667.00K | -1.61M | -1.58M | -1.59M |
| Total Debt Issued | 25.00M | 25.00M | 25.00M | -- | -- |
| Total Debt Repaid | -84.00K | -87.00K | -87.00K | -87.00K | -87.00K |
| Issuance of Common Stock | 15.61M | 12.69M | 6.87M | 3.28M | 179.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 4.51M | 10.92M | 18.82M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.59M | -2.61M | 33.13M | 35.72M | 35.72M |
| Cash from Financing | 37.94M | 34.99M | 69.42M | 49.83M | 54.63M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.25M | -10.00M | 12.68M | -2.70M | 2.46M |